2565 Stock Chart & Stats
HK$43.76
--
Market closed
HK$43.76
--
Day’s Range― - ―
52-Week RangeHK$4.94 - HK$77.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)277.44K
Market Cap
HK$2.63B
Enterprise ValueHK$3.59B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.66
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding386,002,380
10 Day Avg. Volume164,136
30 Day Avg. Volume277,440
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PegBio Co., Ltd. Class H News
2565 FAQ
What was PegBio Co., Ltd. Class H’s price range in the past 12 months?
PegBio Co., Ltd. Class H lowest stock price was HK$4.94 and its highest was HK$77.00 in the past 12 months.
What is PegBio Co., Ltd. Class H’s market cap?
PegBio Co., Ltd. Class H’s market cap is HK$2.63B.
When is PegBio Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PegBio Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is PegBio Co., Ltd. Class H overvalued?
According to Wall Street analysts PegBio Co., Ltd. Class H’s price is currently Overvalued.
Does PegBio Co., Ltd. Class H pay dividends?
PegBio Co., Ltd. Class H does not currently pay dividends.
What is PegBio Co., Ltd. Class H’s EPS estimate?
PegBio Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PegBio Co., Ltd. Class H have?
PegBio Co., Ltd. Class H has 386,002,380 shares outstanding.
What happened to PegBio Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PegBio Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PegBio Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
PegBio Co., Ltd. Class H
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company's PB-718 a long-acting GLP-1 receptor agonist, that have completed b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 an Opioid receptor antagonist, which is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, the company is conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide; and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. PegBio Co., Ltd. was incorporated in 2008 and is based in Hangzhou, China.
Technical Analysis
Yip's Chemical Holdings
―
Tiande Chemical Holdings Limited
―
China Sanjiang Fine Chemicals Co., Ltd.
―
SANVO Fine Chemicals Group Limited
―
Wai Chun Bio-Technology Ltd.
―